sábado, 2 de junio de 2012

A Novartis también le gusta el cannabis / Sativex

Novartis begins filings for cannabis-based Sativex in Middle East
22 November 2011 / Sukaina Virji

Novartis will target filings in the Middle East next as part of its licence agreement with GW Pharmaceuticals for the cannabis-based multiple sclerosis-related spasticity treatment Sativex. These are slated for the first half of 2012, GW's managing director Justin Gover told Scrip.

Más




Ver también:



SATIVEX: Esplendor en la "yerba" para Bayer


Rx marihuana...

No hay comentarios: